Myomo (MYO) Q4 2025 earnings review
Growth Engine Stalls, Forcing a Painful 'Transition Year'
Myomo's hyper-growth narrative hit a wall in Q4. After multiple quarters of triple- and double-digit expansion, revenue growth turned negative, reversing 6% YoY to $11.4 million. The core issue is collapsing advertising efficiency: customer acquisition costs have spiraled out of control, forcing management to aggressively pivot toward recurring, relationship-based channels (O&P clinics and MyoConnect). Consequently, management labeled 2026 a 'transition year,' issuing guidance that implies a drastic deceleration to single-digit growth. While sequential gross margin improvements and promises to halve cash burn offer a defensive silver lining, the short-term reality is a deteriorating bottom line and stalled top-line momentum.
🐂 Bull Case
The pivot is showing early signs of working. Recurring patient sources (U.S./International O&P and MyoConnect) accounted for 42% of Q4 revenue, up significantly from 26% a year ago, providing a more stable base moving forward.
Gross margin expanded 480 basis points sequentially to 68.6% (from 63.8% in Q3), driven by higher volume absorption. A new material cost reduction plan targets an additional 20% improvement by H2 2026.
🐻 Bear Case
Direct-to-consumer advertising efficiency has collapsed. The cost per pipeline add hit $3,039 in Q4, up a staggering 148% YoY. Until the new marketing agency proves effective, the top of the funnel remains severely compromised.
Despite greater overall scale in FY25, Q4 operating losses widened to $2.8M (from $0.2M YoY), and Adjusted EBITDA reversed from a positive $0.2M in 24Q4 to a negative $1.9M.
⚖️ Verdict: 🔴
Bearish. A severe deterioration in marketing efficiency has broken the company's growth trajectory. A 'transition year' with 5-12% growth guidance is a tough pill to swallow for a company that grew 69% in 2024 and 26% in 2025.
Key Themes
Customer Acquisition Cost (CAC) Blowout
The most alarming metric in the report is the cost per pipeline addition. Historically a key operational strength, social media and digital advertising efficiency has completely deteriorated. CAC reached $3,039 in Q4, an accelerating 148% increase YoY. This fundamental breakdown in the direct-to-consumer engine is the primary reason the company's growth has stalled and necessitated a costly strategic pivot.
Pivot to Recurring Patient Channels
To counter the failing direct-advertising model, Myomo is shifting reliance to the Orthotics & Prosthetics (O&P) channel and clinical referrals (MyoConnect). This strategy is bearing fruit: 42% of Q4 revenue came from these recurring sources (up from 26% a year ago), and MyoConnect referrals generated over 10% of Q4 authorizations and orders. If successful, this will structurally lower customer acquisition costs over the long term.
Eroding Earnings Quality and Cash Burn
Operating leverage is moving in the wrong direction. While FY25 revenue grew 26%, Operating Expenses surged 40%. The company burned $14.5M in operating cash flow in FY25 (reversing from a much lower $3.3M burn in FY24). Management claims they will cut cash burn in half in 2026, but executing cost discipline while completely overhauling the sales funnel carries high execution risk.
Material Cost Reduction Initiative
Management announced efforts to reduce material costs by approximately 20%, with full benefits expected by the second half of 2026. This is a critical lever to offset the lower Average Selling Prices (ASP) expected from O&P channel mix shifts and to return gross margins to the target 70%+ range.
Other KPIs
Reversing positively on a sequential basis. Gross margin expanded 480 basis points from Q3's 63.8%, driven by higher sales volumes absorbing overhead. However, it remains below the 71.4% achieved in the prior year quarter due to higher warranty costs and slightly lower ASPs.
Reversing trend. In the prior year quarter (24Q4), Myomo generated its first-ever positive operating cash flow of $3.4 million. The return to negative cash flow highlights the severe impact of rising advertising costs and expanding general operating expenses throughout 2025.
Stable to decelerating. Pipeline additions grew only 3% YoY. Given the 19% increase in quarterly operating expenses (heavily weighted toward marketing), the flat pipeline growth perfectly illustrates the loss of marketing ROI.
Guidance
Decelerating aggressively. The midpoint of $44.5M implies just 8.7% YoY growth, a massive drop-off from 26% growth in FY25 and 69% in FY24. This confirms management's view of 2026 as a strict 'transition year' to fix the acquisition funnel.
Reversing. The midpoint ($9.25M) implies an approximate 6% YoY decline compared to Q1 2025's $9.83M. Management attributes this to historical seasonal patterns, but it also reflects the ongoing friction in direct lead generation.
Management intends to improve operating leverage by keeping OpEx growth to roughly half the rate of revenue growth. This implicitly caps expense increases to ~4% next year, signaling a shift from 'growth at all costs' to strict cash preservation.
Key Questions
Marketing Strategy Overhaul
With the new advertising agency launching television and social media ads, what are the leading indicators that the $3,000+ CAC is reversing, and how much time are you giving this new strategy before considering deeper expense cuts?
Gross Margin Sustainability
You're targeting a 20% reduction in material costs by H2 2026. How much of this will drop to the bottom line versus being used to offset lower ASPs associated with the higher-mix O&P channel?
Debt and Runway
You plan to cut the $14.5M cash burn in half for 2026, leaving you with roughly a $7M burn against $18.4M in liquidity. How does the covenant and principal repayment structure on the $11.2M debt facility influence your timeline to reach cash flow breakeven?